Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
Fenski
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorFlesch
Benjamin Franklin Hospital, Department of Haematology/Oncology, Freie Universität Berlin, Germany
Search for more papers by this authorServe
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorMizuki
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorOelmann
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorKratz-Albers
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorKienast
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorSchwartz
Benjamin Franklin Hospital, Department of Haematology/Oncology, Freie Universität Berlin, Germany
Search for more papers by this authorBerdel
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorServe
Benjamin Franklin Hospital, Department of Haematology/Oncology, Freie Universität Berlin, Germany
Search for more papers by this authorFenski
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorFlesch
Benjamin Franklin Hospital, Department of Haematology/Oncology, Freie Universität Berlin, Germany
Search for more papers by this authorServe
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorMizuki
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorOelmann
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorKratz-Albers
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorKienast
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorSchwartz
Benjamin Franklin Hospital, Department of Haematology/Oncology, Freie Universität Berlin, Germany
Search for more papers by this authorBerdel
University of Münster, Department of Haematology/Oncology
Search for more papers by this authorServe
Benjamin Franklin Hospital, Department of Haematology/Oncology, Freie Universität Berlin, Germany
Search for more papers by this authorAbstract
The receptor tyrosine kinase Flt3 is expressed on leukaemic blasts of most cases with acute myeloid leukaemia (AML). In order to evaluate the presence and significance of constitutive activation of Flt3 for leukaemogenesis, we (1) analysed the expression and activation status of the receptor in AML blasts; and (2) evaluated the functional consequences of constitutively active Flt3 in a myeloid progenitor cell line. Immunoprecipitation studies revealed Flt3 expression in a high proportion of AML cases (27/32) with ligand-dependent Flt3 autophosphorylation in 18, constitutive autophosphorylation in three and no autophosphorylation in six cases. Only one out of three samples with constitutively active Flt3 but 3/18 samples with ligand-dependent autophosphorylated Flt3 contained the recently described internal tandem repeat (ITR) mutations. To test the significance of Flt3 activation in myeloid cell function, we also characterized the biochemical and biological effects of the activating mutation D838V of Flt3 (FLt3D838V) on the factor-dependent myeloid progenitor cell line 32Dcl3: cells transfected with wild-type Flt3 (32D/Flt3) grew FLt3 ligand (FL) dependent, and the receptor was ligand dependently autophosphorylated. In contrast, the receptor was constitutively autophosphorylated in 32D/Flt3D838V cells, which grew independently of FL. We conclude that, in some AML samples, Flt3 is constitutively activated and that this does not correlate with ITR mutations in the juxtamembrane domain. Furthermore, constitutively active Flt3 confers factor independence to the myeloid progenitor cell line 32D. It remains to be determined whether activation of Flt3 is leukaemogenic in vivo and whether strategies aimed at inhibition of Flt3 activation could inhibit leukaemogenesis.
References
- 1 Braun, S.E., Aronica, S.M., Ge, Y., Takahira, H., Etienne-Julan, M., Lu, L., Minden, M.D., Lyman, S.D., Broxmeyer, H.E. (1997) Retroviral mediated gene transfer of Flt3 ligand enhances proliferation and MAP kinase activity of AML5 cells. Experimental Hematology, 25, 51 56.
- 2 Carow, C.E., Levenstein, M., Kaufmann, S.H., Chen, J., Amin, S., Rockwell, P., Witte, L., Borowitz, M.J., Civin, C.I., Small, D. (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood, 87, 1089 1096.
- 3 Daley, G.Q., Van Etten, R.A., Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247, 824 830.
- 4 Dehmel, U., Zaborski, M., Meierhoff, G., Rosnet, O., Birnbaum, D., Ludwig, W.D., Quentmeier, H., Drexler, H.G. (1996) Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia, 10, 261 270.
- 5 Drexler, H.G. (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia, 10, 588 599.
- 6 Eder, M., Hemmati, P., Kalina, U., Ottman, O.G., Hoelzer, D., Lyman, S.D., Ganser, A. (1996) Effects of Flt3 ligand interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells. Experimental Hematology, 24, 371 377.
- 7 Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J.H., Ashman, L.K., Kanayama, Y., Matsuzawa, Y., Kitamura, Y., Kanakura, Y. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. Journal of Clinical Investigations, 92, 1736 1744.
- 8 Gotze, K.S., Ramirez, M., Tabor, K., Small, D., Matthews, W., Civin, C.I. (1998) Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood, 91, 1947 1958.
- 9 Hannum, C., Culpepper, J., Campbell, D., McClanahan, T., Zurawski, S., Bazan, J.F., Kastelein, R., Hudak, S., Wagner, J., Mattson, J., Luh, J., Duda, G., Martina, N., Peterson, D., Menon, S., Shanafelt, A., Muench, M., Kelner, G., Namikawa, R., Rennick, D., Roncarlo, M.-G., Zlotnix, A., Rosnet, O., Dubreuil, P., Birnbaum, D., Lee, F. (1994) Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature, 368, 643 648.
- 10 Hashimoto, K., Tsujimura, T., Moriyama, Y., Yamatodani, A., Kimura, M., Tohya, K., Morimoto, M., Kitayama, H., Kanakura, Y., Kitamura, Y. (1996) Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. American Journal of Pathology, 148, 189 200.
- 11 Hawley, T.S., Fong, A.Z.C., Griesser, H., Lyman, S.D., Hawley, R.G. (1998) Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. Blood, 92, 2003 2011.
- 12 Juan, T.S., Van McNiece, I.K.G., Lacey, D., Hartley, C., McElroy, P., Sun, Y., Argento, J., Hill, D., Yan, X.Q., Fletcher, F.A. (1997) Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood, 90, 76 84.
- 13 Kitayama, H., Tsujimura, T., Matsumura, I., Oritani, K., Ikeda, H., Ishikawa, J., Okabe, M., Suzuki, M., Yamamura, K., Matsuzawa, Y., Kitamura, Y., Kanakura, Y. (1996) Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood, 88, 995 1004.
- 14 Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H., Naoe, T. (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia, 12, 1333 1337.
- 15 Kolibaba, K.S. & Druker, B.J. (1997) Protein tyrosine kinases and cancer. Biochimica Biophysica Acta, 1333, F217 F248.
- 16 Lisovsky, M., Estrov, Z., Zhang, X., Consoli, U., Sanchez-Williams, G., Snell, V., Munker, R., Goodacre, A., Savchenko, V., Andreeff, M. (1996) Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood, 88, 3987 3997.
- 17 Longley, B.J., Tyrrell, L., Lu, S.Z., Ma, Y.S., Langley, K., Ding, T.G., Duffy, T., Jacobs, P., Tang, L.H., Modlin, I. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genetics, 12, 312 314.
- 18 Lyman, S.D. & Jacobsen, S.E. (1998) c-kit ligand Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood, 91, 1101 1134.
- 19 Lyman, S.D., James, L., Vanden Bos, T., De Vries, P., Brasel, K., Gliniak, B., Hollingsworth, L.T., Picha, K.S., McKenna, H.J., Splett, R.R., Fletcher, F.A., Maraskovsky, E., Farrah, T., Foxworthe, D., Williams, D. E., Beckmann, M. P. (1993a) Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell, 75, 1157 1167.
- 20 Lyman, S.D., James, L., Zappone, J., Sleath, P.R., Beckmann, M.P., Bird, T. (1993b) Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene, 8, 815 822.
- 21 Lyman, S.D., James, L., Johnson, L., Brasel, K., De Vries, P., Escobar, S.S., Downey, H., Splett, R.R., Beckmann, M.P., McKenna, H.J. (1994) Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood, 83, 2795 2801.
- 22 Mackarehtschian, K., Hardin, J.D., Moore, K.A., Boast, S., Goff, S.P., Lemischka, I.R. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity, 3, 147 161.
- 23 McKenna, H.J., Smith, F.O., Brasel, K., Hirschstein, D., Bernstein, I.D., Williams, D.E., Lyman, S.D. (1996) Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. Experimental Hematology, 24, 378 385.
- 24 Markowitz, D., Goff, S., Bank, A. (1988) A safe packaging line for gene transfer: separating viral genes on two different plasmids. Journal of Virology, 62, 1120 1124.
- 25 Matthews, W., Jordan, C.T., Wiegand, G.W., Pardoll, D., Lemischka, I.R. (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell, 65, 1143 1152.
- 26 Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911 1918.
- 27 Piacibello, W., Fubini, L., Sanavio, F., Brizzi, M.F., Severino, A., Garetto, L., Stacchini, A., Pegoraro, L., Aglietta, M. (1995) Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood, 86, 4105 4114.
- 28 Piao, X. & Bernstein, A. (1996) A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood, 87, 3117 3123.
- 29 Piao, X., Paulson, R., Van Der Geer, P., Pawson, T., Bernstein, A. (1996) Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proceedings of the National Academy of Sciences of the USA, 93, 14665 14669.
- 30 Qiu, F.H., Ray, P., Brown, K., Barker, P.E., Jhanwar, S., Ruddle, F.H., Besmer, P. (1988) Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family — oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO Journal, 7, 1003 1011.
- 31 Rosnet, O., Marchetto, S., DeLapeyriere, O., Birnbaum, D. (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene, 6, 1641 1650.
- 32 Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M.Z., Gewirtz, A.M., Civin, C.I. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proceedings of the National Academy of Sciences of the USA, 91, 459 463.
- 33 Stacchini, A., Fubini, L., Severino, A., Sanavio, F., Aglietta, M., Piacibello, W. (1996) Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Leukemia, 10, 1584 1591.
- 34 Tsujimura, T., Furitsu, T., Morimoto, M., Isozaki, K., Nomura, S., Matsuzawa, Y., Kitamura, Y., Kanakura, Y. (1994) Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood, 83, 2619 2626.
- 35 Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., Naoe, T. (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11, 1605 1609.